PE20011042A1 - USE OF GLUTAMINE FOR THE PREVENTION OF LATE ONSET DIARRHEA INDUCED BY IRINOTECAN - Google Patents
USE OF GLUTAMINE FOR THE PREVENTION OF LATE ONSET DIARRHEA INDUCED BY IRINOTECANInfo
- Publication number
- PE20011042A1 PE20011042A1 PE2001000027A PE2001000027A PE20011042A1 PE 20011042 A1 PE20011042 A1 PE 20011042A1 PE 2001000027 A PE2001000027 A PE 2001000027A PE 2001000027 A PE2001000027 A PE 2001000027A PE 20011042 A1 PE20011042 A1 PE 20011042A1
- Authority
- PE
- Peru
- Prior art keywords
- irinotecan
- glutamine
- late onset
- prevention
- day
- Prior art date
Links
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 title abstract 3
- 101100020619 Arabidopsis thaliana LATE gene Proteins 0.000 title abstract 2
- 206010012735 Diarrhoea Diseases 0.000 title abstract 2
- UWKQSNNFCGGAFS-XIFFEERXSA-N irinotecan Chemical compound C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1 UWKQSNNFCGGAFS-XIFFEERXSA-N 0.000 title abstract 2
- 229960004768 irinotecan Drugs 0.000 title abstract 2
- 230000002265 prevention Effects 0.000 title 1
- 239000000203 mixture Substances 0.000 abstract 2
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
- 102000004169 proteins and genes Human genes 0.000 abstract 1
- 229910052711 selenium Inorganic materials 0.000 abstract 1
- 239000011669 selenium Substances 0.000 abstract 1
- 229940088594 vitamin Drugs 0.000 abstract 1
- 229930003231 vitamin Natural products 0.000 abstract 1
- 235000013343 vitamin Nutrition 0.000 abstract 1
- 239000011782 vitamin Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
SE REFIERE A UNA COMPOSICION FARMACEUTICA QUE COMPRENDE: a) DE 10gr A 150gr POR DIA DE GLUTAMINA; b) VITAMINAS TAL COMO A, C Y E; c) PROTEINAS; d) SELENIO . LA DOSIS DE GLUTAMINA ES DIVIDIDA EN 2 HASTA 12 DOSIS INDIVIDUALES ADMINISTRADAS PERIODICAMENTE DURANTE EL DIA. LA COMPOSICION ES ADMINISTRADA EL MISMO DIA O AL DIA SIGUIENTE DE LA ADMINISTRACION DE IRINOTECAN. LA COMPOSICION ES UTIL PARA PREVENIR O REDUCIR EL DESARROLLO DE DIARREA CON INICIO TARDIO INDUCIDA POR IRINOTECANIT REFERS TO A PHARMACEUTICAL COMPOSITION THAT INCLUDES: a) FROM 10gr TO 150gr PER DAY OF GLUTAMINE; b) VITAMINS SUCH AS A, C AND E; c) PROTEINS; d) SELENIUM. THE DOSAGE OF GLUTAMINE IS DIVIDED INTO 2 TO 12 INDIVIDUAL DOSES ADMINISTERED PERIODICALLY DURING THE DAY. THE COMPOSITION IS ADMINISTERED ON THE SAME DAY OR ON THE FOLLOWING DAY OF IRINOTECAN'S ADMINISTRATION. THE COMPOSITION IS USEFUL TO PREVENT OR REDUCE THE DEVELOPMENT OF IRINOTECAN-INDUCED LATE ONSET DIARRHEA
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US48496200A | 2000-01-18 | 2000-01-18 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20011042A1 true PE20011042A1 (en) | 2001-09-26 |
Family
ID=23926357
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2001000027A PE20011042A1 (en) | 2000-01-18 | 2001-01-12 | USE OF GLUTAMINE FOR THE PREVENTION OF LATE ONSET DIARRHEA INDUCED BY IRINOTECAN |
Country Status (4)
| Country | Link |
|---|---|
| AU (1) | AU2001229478A1 (en) |
| CO (1) | CO5280204A1 (en) |
| PE (1) | PE20011042A1 (en) |
| WO (1) | WO2001052828A2 (en) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2295429A1 (en) * | 2000-01-06 | 2001-07-06 | Michael Michael | Treatment or prevention of diarrhea |
| WO2004103371A1 (en) * | 2003-05-21 | 2004-12-02 | Pharmacia & Upjohn Company Llc | Use of cftr inhibitors for the treatment of chemotherapy-induced diarrhea |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5786344A (en) * | 1994-07-05 | 1998-07-28 | Arch Development Corporation | Camptothecin drug combinations and methods with reduced side effects |
| US5646159A (en) * | 1994-07-20 | 1997-07-08 | Research Triangle Institute | Water-soluble esters of camptothecin compounds |
-
2001
- 2001-01-12 CO CO01002004A patent/CO5280204A1/en not_active Application Discontinuation
- 2001-01-12 WO PCT/US2001/001270 patent/WO2001052828A2/en not_active Ceased
- 2001-01-12 AU AU2001229478A patent/AU2001229478A1/en not_active Abandoned
- 2001-01-12 PE PE2001000027A patent/PE20011042A1/en not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| AU2001229478A1 (en) | 2001-07-31 |
| WO2001052828A3 (en) | 2002-04-18 |
| WO2001052828A2 (en) | 2001-07-26 |
| CO5280204A1 (en) | 2003-05-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK0954314T3 (en) | Dosage forms for ameliorating male erectile dysfunction | |
| ATE424810T1 (en) | A DELAYED-RELEASE TABLET CONTAINING A HYDROCOLLOID AND A CELLULOSE ETHER | |
| EA200700049A1 (en) | PREPARATIVE FORMS OF ORAL MEDICINAL FORMS OF MEMANTINE WITH MODIFIED SURVIVAL | |
| BRPI0108977B8 (en) | azacyclic compounds, pharmaceutical composition and use of a compound or pharmaceutically acceptable salt thereof | |
| WO2005065069A3 (en) | Pharmaceutical methods, dosing regimes and dosage forms for the treatment of alzheimer's disease | |
| BR0015188A (en) | Pharmaceutical compositions | |
| GEP20053473B (en) | High Potency Dihydroergotamine Compositions | |
| BG66093B1 (en) | Controlled release compositions comprising nimesulide | |
| MY118164A (en) | Pharmaceutical composition comprising a combination of metformin and fibrate, and its use for the preparation of medicines intended to reduce hyperglycaemia | |
| MX2007006212A (en) | Oral medicament for the modified release of at least one active principle, in multimicrocapsule form. | |
| BG106095A (en) | NEW MEDICINAL COMPOSITIONS BASED ON ANTICHLINERGY ACTIVE COMPOUNDS AND BETA-MIMETITIS | |
| YU49026B (en) | THE USE OF 17 ß -(N-TERT-BUTYLCARBAMOYIL)-4-AZA-5-ALPHA-ANDROST-1-ENE-3-ONE FOR THE PREPARATION OF A MEDICAMENT FOR THE TREATMENT OF ANDROGENIC ALOPECIA | |
| DK0680326T3 (en) | Pharmaceutical formulation of nicotine addiction. | |
| BR0211198A (en) | Pharmaceutical compositions and their use | |
| ES2168241T1 (en) | PHARMACEUTICAL PREPARATION CONTAINING TOLPERISONE TO ADMINISTER BY ORAL ROUTE. | |
| AP2003002763A0 (en) | Controlled release formulations for oral administration | |
| MY141012A (en) | Combination comprising an at1-receptor antagonist and an insulin secretion enhancer or an insulin sensitiser | |
| YU36401A (en) | Pharmaceutical composition for modified insulin sensitiser | |
| PL360492A1 (en) | Use of pamoic acid or one of its derivatives, or one of its analogues, for the preparation of a medicament for the treatment of diseases characterised by deposits of amyloid aggregates | |
| ATE311928T1 (en) | (-)-PSEUDOEPHEDRINE AS A SYMPATHOMIMETIC DRUG | |
| DE59914183D1 (en) | DISPOSABLE DEVICE FOR A COMPOSITION OF A PHARMACEUTICALLY ACTIVE SUBSTANCE | |
| PE20011042A1 (en) | USE OF GLUTAMINE FOR THE PREVENTION OF LATE ONSET DIARRHEA INDUCED BY IRINOTECAN | |
| GEP20043377B (en) | Pharmaceutical Complex | |
| AR014082A1 (en) | ORAL SERTRALINE CONCENTRATE | |
| SE0000303D0 (en) | Novel compounds |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |